BRCA1 and familial pancreatic carcinoma: Rucaparib was evaluated in a phase II trial as a maintenance regimen for advanced pancreatic cancer (including both metastatic and locally advanced cases) in patients harboring BRCA1, BRCA2 or PALB2 germline or somatic mutations.